Dr Reddys Laboratories Ltd

Dr Reddy's Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dr Reddys Laboratories Ltd

₹ 1,337 2.54%
15 May - close price
drreddys.com BSE: 500124 NSE: DRREDDY
About

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Key Points

Global Generics Segment (~83% of revenues in FY22)
Co. offers 400+ high-quality generic drugs, keeping costs reasonable by leveraging its integrated operations. The company benefits from its expertise in active ingredients, product development skills, a keen understanding of regulations and intellectual property rights & streamlined supply chain. [1]
Top revenue contributors of the segment are nervous system drugs (14%), gastrointestinal (13%) & anti-infective (10%) [2]
In FY22, co. filed 7 new ANDA’s with US FDA [3]

Website BSE NSE
  • Market Cap ₹ 1,11,569 Cr.
  • Current Price ₹ 1,337
  • High / Low ₹ 1,380 / 1,148
  • Stock P/E 26.6
  • Book Value ₹ 454
  • Dividend Yield 0.60 %
  • ROCE 13.6 %
  • ROE 11.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Dividend payout has been low at 13.2% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
6,315 6,758 6,903 7,237 7,114 7,696 8,038 8,381 8,528 8,572 8,828 8,753 7,546
4,781 4,696 4,894 5,214 5,283 5,566 5,962 6,108 6,530 6,398 6,818 6,866 7,164
Operating Profit 1,534 2,062 2,008 2,023 1,831 2,130 2,076 2,273 1,998 2,174 2,010 1,888 382
OPM % 24% 31% 29% 28% 26% 28% 26% 27% 23% 25% 23% 22% 5%
146 178 319 219 201 193 314 154 528 290 330 271 480
Interest 35 37 35 39 59 60 76 82 66 83 91 94 106
Depreciation 316 353 376 374 368 381 397 471 455 476 505 521 557
Profit before tax 1,329 1,850 1,917 1,829 1,605 1,883 1,917 1,874 2,005 1,905 1,745 1,543 200
Tax % 28% 24% 23% 24% 18% 26% 30% 25% 21% 26% 23% 23% -11%
960 1,405 1,482 1,381 1,310 1,392 1,342 1,404 1,587 1,410 1,337 1,190 221
EPS in Rs 11.53 16.87 17.77 16.56 15.70 16.69 15.05 16.94 19.09 16.99 16.14 14.50 2.65
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
15,023 15,568 14,196 14,281 15,448 17,517 19,048 21,545 24,670 28,011 32,644 33,700
11,515 11,983 11,724 11,930 12,270 15,040 15,173 17,778 18,200 20,078 24,097 27,247
Operating Profit 3,508 3,585 2,472 2,351 3,178 2,477 3,874 3,768 6,470 7,933 8,547 6,454
OPM % 23% 23% 17% 16% 21% 14% 20% 17% 26% 28% 26% 19%
260 295 172 155 381 670 335 555 971 909 1,119 1,372
Interest 108 83 63 79 89 98 97 96 143 171 283 374
Depreciation 760 939 1,027 1,077 1,135 1,163 1,229 1,165 1,250 1,470 1,704 2,059
Profit before tax 2,900 2,859 1,554 1,350 2,336 1,886 2,884 3,061 6,048 7,201 7,680 5,393
Tax % 19% 26% 19% 32% 17% -7% 32% 29% 25% 23% 25% 23%
2,336 2,131 1,292 947 1,950 2,026 1,952 2,182 4,507 5,578 5,725 4,158
EPS in Rs 27.43 24.98 15.59 11.41 23.49 24.38 23.47 26.23 54.14 66.87 67.77 50.27
Dividend Payout % 15% 16% 26% 35% 17% 21% 21% 23% 15% 12% 12% 16%
Compounded Sales Growth
10 Years: 8%
5 Years: 12%
3 Years: 11%
TTM: 3%
Compounded Profit Growth
10 Years: 7%
5 Years: 17%
3 Years: -3%
TTM: -24%
Stock Price CAGR
10 Years: 8%
5 Years: 5%
3 Years: 15%
1 Year: 9%
Return on Equity
10 Years: 15%
5 Years: 17%
3 Years: 17%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 85 85 83 83 83 83 83 83 83 83 83 84
Reserves 9,768 12,484 12,179 12,489 13,941 15,516 17,558 19,129 23,203 28,171 33,466 37,808
4,314 3,352 4,918 5,071 3,838 2,210 3,031 3,384 1,347 2,002 4,677 7,734
4,290 4,408 4,474 4,706 4,557 5,414 5,915 7,149 7,576 8,523 9,797 12,498
Total Liabilities 18,457 20,330 21,654 22,349 22,418 23,223 26,588 29,746 32,209 38,780 48,023 58,123
5,377 6,563 6,931 6,968 7,191 6,850 8,206 8,122 9,219 10,426 18,226 22,063
CWIP 529 772 3,324 3,470 2,934 1,535 1,565 1,293 1,030 1,419 2,466 1,460
Investments 2,248 3,833 2,110 2,298 2,587 2,678 2,212 2,616 4,986 4,930 4,051 5,285
10,303 9,162 9,290 9,612 9,707 12,160 14,605 17,715 16,974 22,004 23,280 29,315
Total Assets 18,457 20,330 21,654 22,349 22,418 23,223 26,588 29,746 32,209 38,780 48,023 58,123

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,524 3,263 2,144 1,803 2,870 2,984 3,570 2,811 5,888 4,543 4,643 5,674
-2,370 -1,610 -1,890 -1,483 -769 -495 -2,255 -2,565 -4,109 -4,034 -5,785 -6,549
-433 -1,700 -369 -444 -2,133 -2,516 -30 -242 -2,686 -376 1,891 829
Net Cash Flow -280 -47 -114 -124 -31 -27 1,286 3 -907 133 749 -47
Free Cash Flow 1,009 2,065 926 713 2,248 2,412 2,323 1,238 4,009 1,908 1,327 2,004
CFO/OP 88% 111% 110% 88% 106% 149% 107% 94% 108% 83% 78% 109%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 100 97 98 104 94 105 95 113 107 105 101 110
Inventory Days 248 248 282 263 273 230 273 250 232 283 260 228
Days Payable 84 88 104 121 111 100 109 111 108 116 97 91
Cash Conversion Cycle 264 257 275 246 256 235 259 252 231 271 264 247
Working Capital Days 26 34 -14 39 65 59 57 61 84 118 69 109
ROCE % 22% 19% 9% 8% 13% 11% 16% 14% 27% 27% 23% 14%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend as % of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
ANDA Filings (US)
Number
Pending ANDAs (USFDA)
Number
Global DMF Filings
Number
New Global Product Launches
Number
Global Patient Reach
Million Patients
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
26.69% 26.66% 26.65% 26.65% 26.65% 26.64% 26.64% 26.64% 26.64% 26.64% 26.64% 26.63%
26.99% 28.19% 28.62% 29.13% 27.68% 27.53% 26.85% 25.75% 25.33% 24.69% 22.34% 21.14%
21.99% 21.04% 18.65% 18.31% 20.72% 21.48% 22.89% 25.63% 26.73% 27.99% 30.44% 30.72%
24.11% 23.93% 25.89% 25.73% 24.78% 24.20% 23.46% 21.69% 21.04% 20.45% 20.33% 21.27%
0.21% 0.18% 0.18% 0.17% 0.17% 0.16% 0.16% 0.29% 0.26% 0.25% 0.25% 0.24%
No. of Shareholders 2,46,7692,43,4452,57,7942,55,5002,67,6943,10,4034,03,6694,59,6054,51,9294,49,2164,55,2434,49,665

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls